

Jean-Sebastien Frenel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920242/publications.pdf>

Version: 2024-02-01

65
papers

2,469
citations

361296
20
h-index

206029
48
g-index

79
all docs

79
docs citations

79
times ranked

4976
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress. <i>Psycho-Oncology</i> , 2022, 31, 848-855.	1.0	6
2	Real-world evidence of the management and prognosis of young women (≥40 years) with de novo metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110703.	1.4	4
3	Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210770.	1.4	2
4	Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. <i>Cancers</i> , 2022, 14, 1156.	1.7	6
5	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
6	Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4272.	1.2	2
7	Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review. <i>Cancers</i> , 2022, 14, 172.	1.7	2
8	Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2509.	1.7	22
9	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	13
10	Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e2113739.	2.8	19
11	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	1.4	55
12	Cell-free circulating epimarks in cancer monitoring. <i>Epigenomics</i> , 2020, 12, 145-155.	1.0	8
13	Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098054.	1.4	1
14	Benefits versus risk profile of buparlisib for the treatment of breast cancer. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 553-562.	1.0	10
15	Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 537-542.	1.1	1
16	Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 85-91.	1.5	5
17	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	0.6	2
18	The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 50-68.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open, 2018, 3, e000285.	2.0	169
20	5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. European Journal of Cancer, 2018, 95, 30-37.	1.3	26
21	Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 559-566.	1.1	26
22	miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker. Molecular Therapy - Nucleic Acids, 2018, 13, 642-650.	2.3	21
23	Emerging PARP inhibitors for treating breast cancer. Expert Opinion on Emerging Drugs, 2018, 23, 211-221.	1.0	10
24	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology, 2018, 29, 2334-2340.	0.6	97
25	An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer. Drugs, 2018, 78, 1353-1362.	4.9	6
26	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux â€‘M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. Journal of Clinical Oncology, 2018, 36, 2023-2023.	0.8	10
27	Feasibility and benefit of molecularly-informed enrollment into early phase trials for patients with recurrent gliomas.. Journal of Clinical Oncology, 2018, 36, 2004-2004.	0.8	0
28	Olaparib for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 751-759.	1.9	20
29	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 335-346.	1.4	39
30	Management of Fournier's gangrene non-healing wounds by autologous skin micrograft biotechnology: a new technique. Journal of Wound Care, 2017, 26, 314-317.	0.5	9
31	Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses. Future Oncology, 2017, 13, 2667-2680.	1.1	12
32	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1â€‘Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology, 2017, 35, 4035-4041.	0.8	375
33	Efficacy of buparlisib in treating breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 2007-2016.	0.9	8
34	An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1) Tj ETQq0 0 0 rgBT /Overlock 1 tumors. Anti-Cancer Drugs, 2016, 27, 342-348.	0.7	12
35	Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. Clinical Colorectal Cancer, 2016, 15, e165-e174.	1.0	9
36	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	3.2	105

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 307-318.	1.1	101
38	Vinflunine for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1817-1823.	0.9	10
39	Aquacel Surgical Dressing after Thigh Lift. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2016, 4, e863.	0.3	1
40	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2019-2019.	0.8	14
41	Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5515-5515.	0.8	53
42	MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2083-TPS2083.	0.8	0
43	Outcome and follow-up of glioblastoma patients treated with bevacizumab based therapy in 2nd line treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13502-e13502.	0.8	0
44	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	3.2	171
45	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015, 85, 1325-1331.	1.5	34
46	Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-550.	0.8	118
47	Efficacy and Safety of Bevacizumab (Bv) and Irinotecan (I) in Elderly Patients with Recurrent Glioblastoma Multiform (Gbm): a Monocentric Retrospective Study. <i>Annals of Oncology</i> , 2014, 25, iv143.	0.6	0
48	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014, 6, 254ra125.	5.8	298
49	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoradiation with temozolomide in newly diagnosed glioblastoma without methylation of the <i>MGMT</i> gene promoter.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2003-2003.	0.8	13
50	Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11051-11051.	0.8	0
51	Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. <i>Journal of Neuro-Oncology</i> , 2013, 114, 85-91.	1.4	28
52	Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. <i>Annals of Oncology</i> , 2013, 24, 916-924.	0.6	43
53	bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: the <i>Journal of Biological Databases and Curation</i> , 2013, 2013, bas060-bas060.	1.4	211
54	Abstract 1189: Phase I (phI) study evaluating the cardiac safety of oral chemotherapy s-1 in patients (pts) with advanced solid tumors.. , 2013, , .		1

#	ARTICLE	IF	CITATIONS
55	What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?. Expert Review of Anticancer Therapy, 2012, 12, 195-201.	1.1	0
56	Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer. Clinical Investigation, 2012, 2, 207-213.	0.0	2
57	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. International Journal of Oncology, 2012, 40, 2058-62.	1.4	23
58	Phase I en oncologie. Le défi de développer de nouveaux agents thérapeutiques à l'ère de la médecine personnalisée. Medecine Nucleaire, 2012, 36, 228-232.	0.2	0
59	Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases. European Journal of Surgical Oncology, 2011, 37, 971-977.	0.5	16
60	NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment. PLoS ONE, 2011, 6, e22845.	1.1	12
61	Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. Journal of Surgical Oncology, 2011, 103, 10-16.	0.8	46
62	Eribulin mesylate for the treatment of late-stage breast cancer. Expert Opinion on Pharmacotherapy, 2011, 12, 2883-2890.	0.9	17
63	Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003. Cancer Epidemiology, 2010, 34, 238-243.	0.8	24
64	Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. British Journal of Cancer, 2008, 98, 1993-1998.	2.9	64
65	PD5-3-2: Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S479.	0.5	0